Topic Code
HORIZON-HLTH-2026-01-TOOL-03
F&T Portal
Call Identifier
HORIZON-HLTH-2026-01
Call 01 — single stage (2026)
Instrument
HORIZON-RIA
Research and Innovation Action
Budget Model
Lump Sum
HORIZON-AG-LS
Funding Rate
100%
Annex G — RIA = 100%
Page Limit (Part B)
45 pages
RIA + lump sum (Annex A)
Evaluation Thresholds
4 / 4 / 4 · cum. 12
Non-standard — topic override
Expected Projects
7
€5–8M per project (WP stated)
Destination
Developing and using new tools, technologies and digital solutions for a healthy society
WP Part 4
Cluster / Pillar
Cluster 1 / Pillar II
Health
China Eligibility
Excluded ⚠
Destination excludes RIA/IA
Special Conditions
Clustering required
Joint activities WP (~2% budget)
Chinese entities are excluded from RIA actions under this destination. Legal entities established in China are not eligible to participate in Research and Innovation Actions (RIAs) falling under Destination ‘Developing and using new tools, technologies and digital solutions for a healthy society’.
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
Communication networks restriction: Entities assessed as high-risk suppliers of mobile network communication equipment (and entities they own or control) are not eligible to participate in this topic.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.
Expected Outcomes
- Researchers are in possession of improved human-relevant New Approach Methodologies (NAMs) platforms that capture the genetic, phenotypic, age-related, immune, microbiome, and environmental exposure variability of the human population. These innovations support more equitable healthcare solutions and personalised treatment strategies across diverse life stages.
- Industry gets access to platforms that allow a faster pace of innovation for the development of more cost-effective targeted therapeutic interventions and improvement of the safety assessment of chemicals, other medicinal products, and medical devices.
- Patients benefit from innovative platforms and strategies that improve prediction, prevention and treatment of diseases, in particular through enhanced understanding of disease pathways and mechanisms.
- The general population is better protected through a safer environment, as these platforms enhance the detection and mitigation of risks posed by chemicals and other potentially harmful substances.
- Regulatory bodies gain confidence and trust in NAMs, supporting their integration into product development, risk assessment, and approval processes.
- Fewer live animals are used in biomedical research and regulatory testing.
Want the full analysis?
The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.
Compliance traps
Scoring playbook
Consortium blueprint
Positioning guide
Red flags
Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day